PT  - JOURNAL ARTICLE
AU  - Dornburg, Alex
AU  - Hassler, Hayley B.
AU  - Townsend, Jeffrey P.
TI  - Assessing COVID-19 infection probabilities in response to alternate vaccine boosting frequencies for multiple-sclerosis patients undergoing disease-modifying therapy with beta-interferon, dimethyl fumarate, natalizumab, or teriflunomide
AID  - 10.1101/2024.09.19.24313891
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.09.19.24313891
4099  - http://medrxiv.org/content/early/2024/09/22/2024.09.19.24313891.short
4100  - http://medrxiv.org/content/early/2024/09/22/2024.09.19.24313891.full
AB  - Multiple sclerosis patients treated with disease-modifying therapies experience varying immune responses to COVID-19 vaccinations. However, guidance regarding the impact of treatments on infection risks remains sparse. Integrating vaccine-based and long-term coronavirus infection-based antibody data, we calculated cumulative probabilities of breakthrough infection for untreated multiple sclerosis patients and patients treated with interferon, dimethyl fumarate, natalizumab, or teriflunomide undergoing alternative Pfizer-BioNTech BNT162b2 booster frequencies. Annual boosters appear to effectively reduce risks for untreated multiple sclerosis patients. For treated patients, booster vaccinations likely provide protection that is nearly equivalent to that obtained in untreated patients, with moderate treatment-specific increases and decreases in immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Science Foundation RAPID DEB 2031204 to JPT and AD and the National Science Foundation CCF 1918784 to JPT.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes